Fig. 2.

a The Kaplan–Meier distribution of progression-free survival (PFS). Patients with advanced gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction were randomly assigned to receive docetaxel, cisplatin, and 5-fluorouracil (DCF) or cisplatin and 5-fluorouracil (CF). b PFS [hazard ratios (HR) and 95 % confidence intervals (CI)] for selected subgroup analyses. c The Kaplan–Meier distribution of overall survival (OS). KPS Karnofsky performance status, LCL lower confidence limit, UCL upper confidence limit